Cancer cell-intrinsic expression of MHC II in lung cancer cell lines is actively restricted by MEK/ERK signaling and epigenetic mechanisms

BACKGROUND: Programmed death 1/programmed death ligand 1 (PD-1/PD-L1) targeted immunotherapy affords clinical benefit in ~20% of unselected patients with lung cancer. The factor(s) that determine whether a tumor responds or fails to respond to immunotherapy remains an active area of investigation. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuwelt, Alexander J, Kimball, Abigail K, Johnson, Amber M, Arnold, Benjamin W, Bullock, Bonnie L, Kaspar, Rachael E, Kleczko, Emily K, Kwak, Jeff W, Wu, Meng-Han, Heasley, Lynn E, Doebele, Robert C, Li, Howard Y, Nemenoff, Raphael A, Clambey, Eric T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204826/
https://www.ncbi.nlm.nih.gov/pubmed/32312906
http://dx.doi.org/10.1136/jitc-2019-000441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204826/
https://www.ncbi.nlm.nih.gov/pubmed/32312906
http://dx.doi.org/10.1136/jitc-2019-000441

Ejemplares similares